Application of propionyl carnitine in improvement of obesity and insulin resistance

By using propionylcarnitine as a pharmaceutical composition, the problem of obesity and NAFLD caused by intestinal homeostasis disruption has been solved, achieving the effects of weight reduction, improved insulin resistance and reduced adipose tissue inflammation, providing a new method for treating obesity and related metabolic diseases.

CN122075465APending Publication Date: 2026-05-26BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIVERSITY
Filing Date
2024-11-25
Publication Date
2026-05-26

Smart Images

  • Figure HDA0005151924570000011
    Figure HDA0005151924570000011
  • Figure HDA0005151924570000021
    Figure HDA0005151924570000021
  • Figure HDA0005151924570000031
    Figure HDA0005151924570000031
Patent Text Reader

Abstract

The invention provides application of propionyl carnitine in improvement of obesity and insulin resistance. Specifically, the invention finds that the propionyl carnitine has the effects of improving obesity and insulin resistance in a diet-induced obese mouse model, so that the application of the propionyl carnitine in treating obesity and obesity-related metabolic diseases is provided.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Biomarker combination for evaluating Alzheimer's disease and application and kit thereof

    CN113917034A

  • Coronary heart disease metabolism marker and application thereof in diagnosis and prognosis

    CN114324641A

  • Metabolites for the preparation of drugs for treating liver cancer and their applications

    CN114522158B